Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib dose escalation in metastatic renal cell carcinoma
NCT00854620Phase 2Completed
- Sponsor
- Stanford University
- Start
- Dec 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in metastatic renal cell carcinoma (mRCC), sponsored by Stanford University. Started Dec 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00854620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00854620.